Nectin-4, despite being a well-established oncology target, is currently underutilized in drug development compared to HER2, TROP2, and Claudin18.2. However, its significant potential is underscored by its prevalent overexpression in various cancer types, such as pancreatic, ovarian, cervical, head-and-neck, breast, lung, and urothelial cancers.
As a cell adhesion molecule, Nectin-4 facilitates tissue growth and is selectively upregulated in cancer tissues, making it an attractive candidate for targeted cancer therapies. Despite limited attention from pharmaceutical companies, the development of drugs targeting Nectin-4 holds promising market prospects, necessitati...
